Home › NCT05858632

Immune Spatial Features of Guselkumab Cutaneous Response

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria: possess a PSSI (psoriasis scalp severity index) of ≥12

Exclusion Criteria:

1. taking systemic immunosuppressives in the last 4 weeks
2. pregnancy
3. severe immunodeficiency (either from genetic or infectious causes).
4. tuberculosis or other active serious infection
5. active systemic malignancy.
6. breast-feeding
7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
8. Males who are trying to conceive

   \-

About the study

This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.

What is being tested

• Guselkumab (drug)

Sponsor: University of California, San Francisco · Participants: 10 · Started: Jul 1, 2023

Contact the study team

• Jeffrey Cheng, MD, PhD · Phone: 415 575 0524

Official record on ClinicalTrials.gov — NCT05858632

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.